FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 165 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Latest episode of our podcast for cancer researchers March 23, 2022 GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... December 21, 2020 Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab February 4, 2021 Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients... June 15, 2023 Load more HOT NEWS Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of... COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... No Link Between Caffeine Consumption and Breast Cancer, Study Finds
